Gujarat Kidney And Super Speciality financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹34.3cr 
Net profit
₹5.3cr 
EBITDA margin
24.4% 
EPS
₹0.66 

Quarterly results

Every quarter ›
₹ croreQ1 FY27Year beforeChange
Revenue34.3——
EBITDA8.4——
EBITDA margin24.4%——
Profit before tax7.0——
Net profit5.3——
EPS₹0.66——

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹34.3 crNet profit₹5.3 crNet margin15.5%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026
1,352—
13.313.3
2.22.2
15.715.7
1,357—
10182.0
26.726.9
26.4%32.9%
21.522.2
16.716.8
16.6%20.5%
₹2.01₹1.97
—−3.9
—−10.8
−14.7−14.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GKSL₹171.50

Gujarat Kidney And Super Speciality Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,352 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization—1,352.2
- Cash, Equiv & ST Investments13.313.3
+ Minority Interest2.22.2
+ Total Debt15.715.7
Enterprise Value—1,356.8
Revenue82.0101.0
EBITDA26.926.7
Margin %32.8526.42
EBIT22.221.5
Net Income16.816.7
Margin %20.5016.56
EPS, Adj (current shares)1.972.01
Cash from Operations-3.9—
Capital Expenditures-10.8—
Free Cash Flow-14.7-14.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Gujarat Kidney And Super Speciality financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Gujarat Kidney And Super Speciality (NSE: GKSL) had a market capitalisation of ₹1,355 crore at the 29 October 2026 close (₹171.87 a share), a PE ratio of 85.6 on the last four quarters' profit and a price-to-book ratio of 5.37. In FY26 its consolidated net profit was ₹15.5 crore on revenue of ₹82 crore; in Q1 FY27 (April–June 2026) it was ₹5.2 crore. Its debt-to-equity ratio was 0.06 on 31 March 2026. Promoters held 71.45% of the shares on 30 September 2026.

Share price used
₹171.87 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Gujarat Kidney And Super Speciality at a glance · consolidated

Market cap
₹1,355 Crat ₹171.87 · 29 Oct close
PE ratio (last 4 quarters)
85.687.4 on FY26 profit
Price to book (PB)
5.37book value ₹32.03 a share
Debt to equity
0.06net cash ₹40.6 Cr
Promoter holding
71.45%unchanged vs 30 Jun 202630 September 2026
Net worth
₹253 Cr31 March 2026

Questions

What is the Gujarat Kidney And Super Speciality PE ratio today?

Gujarat Kidney And Super Speciality's PE ratio is 85.6 at the 29 October 2026 close (₹171.87 a share): a market capitalisation of ₹1,355 crore divided by consolidated net profit of ₹15.8 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹15.5 crore) it is 87.4.

What is the Gujarat Kidney And Super Speciality PB ratio (price to book value)?

Gujarat Kidney And Super Speciality's price-to-book (PB) ratio is 5.37 at the 29 October 2026 close: a market capitalisation of ₹1,355 crore divided by shareholders' equity (book value) of ₹253 crore on 31 March 2026. That is a book value of ₹32.03 per share against a share price of ₹171.87.

Is Gujarat Kidney And Super Speciality debt free?

No. Gujarat Kidney And Super Speciality had borrowings of ₹15.7 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.06. Its cash and current investments were ₹56.3 crore, so it held net cash of ₹40.6 crore.

What is the Gujarat Kidney And Super Speciality market cap?

Gujarat Kidney And Super Speciality's market capitalisation was ₹1,355 crore at the 29 October 2026 close: 7.88 crore shares at ₹171.87 each.

What is the Gujarat Kidney And Super Speciality debt to equity ratio?

Gujarat Kidney And Super Speciality's debt-to-equity ratio was 0.06 on 31 March 2026: borrowings of ₹15.7 crore against total equity of ₹255 crore.

What is the Gujarat Kidney And Super Speciality EPS?

Gujarat Kidney And Super Speciality's basic earnings per share (EPS) were ₹2.49 in FY26.

What is the Gujarat Kidney And Super Speciality net worth?

Gujarat Kidney And Super Speciality's net worth — shareholders' equity in its consolidated balance sheet — was ₹253 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹1,355 crore at the 29 October 2026 close.

What is the Gujarat Kidney And Super Speciality book value per share?

Gujarat Kidney And Super Speciality's book value per share was ₹32.03 on 31 March 2026: shareholders' equity of ₹253 crore divided by the 7.88 crore shares in issue. The share price at the 29 October 2026 close was ₹171.87.

What is the Gujarat Kidney And Super Speciality shareholding pattern?

On 30 September 2026, Gujarat Kidney And Super Speciality's shares were held by promoters 71.45%, foreign portfolio investors (FII/FPI) 6.53%, domestic institutions (DII) 0.26% (including mutual funds at 0.00%) and retail and other non-institutional investors 21.77%.

What is the Gujarat Kidney And Super Speciality promoter holding?

Promoters held 71.45% of Gujarat Kidney And Super Speciality on 30 September 2026, unchanged from the previous quarter, according to the shareholding pattern filed with NSE.

What is the Gujarat Kidney And Super Speciality free cash flow?

In FY26, Gujarat Kidney And Super Speciality generated ₹3.9 crore of cash from operations and spent ₹10.8 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹14.7 crore.

What are the Gujarat Kidney And Super Speciality latest quarterly results?

Gujarat Kidney And Super Speciality's latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹5.2 crore; revenue from operations ₹34.3 crore.

What is the Gujarat Kidney And Super Speciality revenue and profit in FY26?

In FY26 (April 2025–March 2026), Gujarat Kidney And Super Speciality's consolidated net profit was ₹15.5 crore, on revenue from operations of ₹82 crore.

When are the Gujarat Kidney And Super Speciality next results?

Gujarat Kidney And Super Speciality will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.

How does Gujarat Kidney And Super Speciality compare with its peers?

On FY26 consolidated figures, against GPT Healthcare, Shalby and Indraprastha Medical Corporation: Gujarat Kidney And Super Speciality's operating margin of 27.1% is the highest of the four (GPT Healthcare 12.1%, Shalby 6.4%, Indraprastha Medical Corporation 15.1%; peer average 11.2%).

How does the Gujarat Kidney And Super Speciality PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Gujarat Kidney And Super Speciality's PE ratio is 87.4, the highest of the four: GPT Healthcare 26.6, Shalby 35.1 and Indraprastha Medical Corporation 15.9, a peer average of 25.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Gujarat Kidney And Super Speciality vs GPT Healthcare: how do they compare?

In FY26, Gujarat Kidney And Super Speciality earned net profit of ₹15.5 crore on revenue of ₹82 crore, against ₹42.2 crore on ₹473 crore for GPT Healthcare. Gujarat Kidney And Super Speciality's operating margin was 27.1% (GPT Healthcare 12.1%). At the 29 October 2026 close, Gujarat Kidney And Super Speciality's market capitalisation was ₹1,355 crore against ₹1,123 crore for GPT Healthcare, and its PE ratio on FY26 profit 87.4 against 26.6.

Where do these Gujarat Kidney And Super Speciality figures come from?

From Gujarat Kidney And Super Speciality's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.